COMPETITION:
Myogence is the only amino acid-based formula granted a US patent for "enhancing physical performance." And, moreover, it is directly tied to the foundational research of total parenteral nutrition (TPN) and intravenous hyperalimentation (IVH) by Dr. Dudrick.
The Dudrick pioneered and TPN inspired nutrient substrate delivery technology offers a unique product line technology.
Unlike energy enhancement products that contain sugars, caffeine or herbal compounds (and often additional ingredients as "anabolic steroids" or "metabolic enhancers"), Myogence works by way of an amino acid substrate delivery modality using the most basic elements necessary for optimal cellular nutrition. This advantage, in part, allows a specific nutritional profile to cross the intestinal mucosa into the blood more expeditiously, which means less energy expenditure in the metabolic process itself. It is hypothesized that the Myogence power and endurance boost is partially explained by energy being more available for activity, and for a longer period of time.
Likewise, the IV anti-atherosclerosis treatment Atheromine enjoys a US patent and is based on the same principles. And, thereby, it is markedly different in character from other pharmaceuticals such as Lipitor® and Crestor®, which aim at lowering cholesterol and anti-atherosclerotic effects, both in its mode of delivery and in an associated lack of side effects. The oral formulation of Atheromine promises to extend this approach in a pill, capsule or liquid form - yet while retaining the advantages of amino acid substrate delivery.
In elegance, metabolically speaking, and in the lack of side effects (sometimes directly associated with metabolic challenge to various enzyme dependent pathways), both proprietary formulas are unique in clinical approach and in terms of market presence. The two products, Atheromine and Myogence, and their underlying approach, enjoy significant competitive advantage vis-a-vis other treatment options and energy products.
GHPC will also enjoy another decisive advantage to market penetration, as most experts in nutrition and many personal trainers know of Dr. Stanley J. Dudrick. These invaluable "opinion makers" identify him and his work at the forefront of scientifically valid and safe nutritional intervention. The "Dudrick Difference", then, will open doors both clinically and to wider consumer markets.
Safety, reputation, and results with products geared around core level nutritional delivery, capable of addressing multiple disease and life stage scenarios, all combine to place GHPC's brand in an enviable competitive, if not clearly superior, position with popular energy/performance supplements or "hard core" pharmaceutical interventions targeting CVD. Backed by medical professionals, GHPC will advance products that reflect rigorous empirical and scientific criteria, winning an exceptional level of credibility, trust and integrity presently lacking in the industry.